Key facts
- This page summarizes Satyajit Kumar Mitra's Form 4 filing for Peak Bio, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 Nov 2022, 21:53.
Satyajit Kumar Mitra - 01 Nov 2022 Form 4 Insider Report for Peak Bio, Inc.
- Reporting relationship
- Executive Director, Head of Oncology
- Issuer ticker
- N/A
- Reported as of
- 01 Nov 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Satyajit Kumar Mitra
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Satyajit Kumar Mitra filed Form 4 for Peak Bio, Inc. on 03 Nov 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PKBO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +18,647
- Change %
- Price
- Shares after
- 18,647
- Date
- 01 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,647
- Exercise price
- $6.10
- Footnotes
- F1
PKBO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +31,700
- Change %
- Price
- Shares after
- 31,700
- Date
- 01 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 31,700
- Exercise price
- $8.05
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Received pursuant to the consummation of the transactions contemplated by that certain Business Combination Agreement (the "Business Combination Agreement") between Ignyte Acquisition Corp. (the former name of the Issuer), a Delaware corporation, Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea ("Legacy Peak Bio"), and Ignyte Korea Co., Ltd., a corporation organized under the laws of the Republic of Korea. These stock options represent Legacy Peak Bio stock options and were initially granted to the Reporting Person on June 12, 2019 and are fully vested.
Footnote F2
Received pursuant to the consummation of the transactions contemplated by the Business Combination Agreement. These stock options represent Legacy Peak Bio stock options and were initially granted to the Reporting Person on January 26, 2022. The stock options become fully vested and exercisable after two years from the initial date of grant, subject to the Reporting Person's continued employment with the Issuer.
SEC remarks
Executive Director, Head of Oncology